Patents by Inventor Raphael Paul Viscidi

Raphael Paul Viscidi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BK VIRUS SEROLOGY ASSESSMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK
    Publication number: 20190107544
    Abstract: The present invention provides methods, compositions, kits, etc. related to the assessment of progressive multifocal leukoencephalopathy (PML) risk, based upon detecting the presence, absence and/or relative levels of serum antibody to BK virus and/or other indication of BK virus infection of a subject, in a subject and/or a sample of a subject. In certain embodiments, such assessment can also include detection of the presence or absence of serum antibody to JC virus in a subject and/or a sample of a subject, optionally to improve the predictive power of such risk assessment.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 11, 2019
    Inventor: Raphael Paul Viscidi
  • POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES
    Publication number: 20170327543
    Abstract: The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle (VLP) vaccines. In one embodiment, a chimeric papillomavirus virus-like particle (VLP) comprises the L1 protein, wherein the HI loop of the L1 protein comprises negatively charged amino acids. In a more specific embodiment, a chimeric bovine papillomavirus VLP comprises the L1 protein, wherein the amino acid sequence EEEEEEEEC is inserted into the HI loop of the L1 protein.
    Type: Application
    Filed: January 31, 2017
    Publication date: November 16, 2017
    Inventors: Raphael Paul Viscidi, Ioannis Bossis
  • Polyionic papilloma virus-like particle (VLP) vaccines
    Patent number: 9580474
    Abstract: The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle (VLP) vaccines. In one embodiment, a chimeric papillomavirus virus-like particle (VLP) comprises the L1 protein, wherein the HI loop of the L1 protein comprises negatively charged amino acids. In a more specific embodiment, a chimeric bovine papillomavirus VLP comprises the L1 protein, wherein the amino acid sequence EEEEEEEEC is inserted into the HI loop of the L1 protein.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: February 28, 2017
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Raphael Paul Viscidi, Ioannis Bossis
  • BK VIRUS SEROLOGY ASSESSMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) RISK
    Publication number: 20160223565
    Abstract: The present invention provides methods, compositions, kits, etc. related to the assessment of progressive multifocal leukoencephalopathy (PML) risk, based upon detecting the presence, absence and/or relative levels of serum antibody to BK virus and/or other indication of BK virus infection of a subject, in a subject and/or a sample of a subject. In certain embodiments, such assessment can also include detection of the presence or absence of serum antibody to JC virus in a subject and/or a sample of a subject, optionally to improve the predictive power of such risk assessment.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 4, 2016
    Inventor: Raphael Paul VISCIDI
  • POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES
    Publication number: 20140050753
    Abstract: The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle (VLP) vaccines. In one embodiment, a chimeric papillomavirus virus-like particle (VLP) comprises the L1 protein, wherein the HI loop of the L1 protein comprises negatively charged amino acids. In a more specific embodiment, a chimeric bovine papillomavirus VLP comprises the L1 protein, wherein the amino acid sequence EEEEEEEEC is inserted into the HI loop of the L1 protein.
    Type: Application
    Filed: September 8, 2011
    Publication date: February 20, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Raphael Paul Viscidi, Ioannis Bossis